NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye injection could reduce treatment frequency for wet AMD
Disease control Recruiting nowThis early-stage trial tests a new medicine called EYC-0305, given as an eye injection every 24 weeks, in 30 people aged 50 and older with wet age-related macular degeneration (AMD). The main goal is to check if the treatment is safe and tolerable. Researchers will also measure h…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Eyconis INC. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
One-Time gene shot could cut eye injections for wet AMD
Disease control Recruiting nowThis study tests a gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single injection into the eye can safely reduce the need for regular anti-VEGF shots. About 215 adults aged 50 and old…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC